Affiliation:
1. S.M.S. Pharmaceuticals Ltd., R&D Center (DSIR approved), Gagillapur (V), Rangareddy-500047, India
Abstract
Raltegravir sodium synthesis was achieved from its one of the key starting materials with retro synthetic approach, in which without using its critical starting material chemically known as 5-methyl-1,3,4-oxadiazole-2-carbonyl chloride and which is more unstable during the synthesis of raltegravir potassium. Almost all the existed literatures commonly using this starting material in its synthesis even it is having a stability issue and hence to achieve a stable and economically viable synthesis. The current research describes a new route of synthesis by constructing an oxadiazole ring in a retro synthetic manner.
Publisher
Asian Journal of Chemistry
Reference24 articles.
1. Highly selective synthesis of 2-substituted-5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid derivatives using a novel protected dihydroxyfumarate
2. B.S. Reddy, S.J.M. Reddy, D.S. Reddy, G.B. Shankar, A. Kishore, Y.S. Somannavark and M. Sivakumaran, An Improved Process for the Preparation of Raltegravir, Patent No: WO/2016075605 (2016).
3. Synthesis of 5,6-dihydroxy-2-phenyl-4-pyrimidinecarboxylic acid, methyl ester, a corrected structure
4. HCV NS5b RNA-Dependent RNA Polymerase Inhibitors: From α,γ-Diketoacids to 4,5-Dihydroxypyrimidine- or 3-Methyl-5- hydroxypyrimidinonecarboxylic Acids. Design and Synthesis
5. Active site inhibitors of HCV NS5B polymerase. The development and pharmacophore of 2-thienyl-5,6-dihydroxypyrimidine-4-carboxylic acid